Benchmark analyst Mark Miller maintains Western Digital (NASDAQ:WDC) with a Buy and lowers the price target from $85 to $65.
AbbVie Announces Lutikizumab Showed Results In A Phase 2 Trial Of Adults With Moderate To Severe Hidradenitis Suppurativa As Program Advances To Phase 3
Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at
